Justin Ferdinandus
Overview
Explore the profile of Justin Ferdinandus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heger J, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmuller J, et al.
J Clin Oncol
. 2024 Sep;
42(35):4218-4230.
PMID: 39348625
Purpose: Current clinical challenges in Hodgkin lymphoma (HL) include difficult-to-treat relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical risk factors lack discriminatory power, intensity of therapy is mainly...
2.
Pabst K, Kessler L, Ferdinandus J, Hamacher R, Bartel T, Siveke J, et al.
EJNMMI Res
. 2024 Jul;
14(1):66.
PMID: 39023777
Purpose: Radiolabelled fibroblast activation protein inhibitors (FAPIs) are becoming increasingly important for imaging various tumour diseases. However, it is essential to be aware of potential pitfalls. Here, we investigate FAP...
3.
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, et al.
Lancet
. 2024 Jul;
404(10450):341-352.
PMID: 38971175
Background: Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With...
4.
Kessler L, Hirmas N, Pabst K, Hamacher R, Ferdinandus J, Schaarschmidt B, et al.
J Nucl Med
. 2023 Nov;
64(12):1910-1917.
PMID: 37973185
The fibroblast activation protein (FAP) is highly expressed on carcinoma-associated fibroblasts in the stroma of pancreatic cancer and thus is a promising target for imaging and therapy. Preliminary data on...
5.
Ferdinandus J, van Heek L, Roth K, Dietlein M, Eich H, Baues C, et al.
Eur J Nucl Med Mol Imaging
. 2023 Sep;
51(2):490-495.
PMID: 37735258
Purpose: Response-adapted treatment using early interim functional imaging with PET after two cycles of chemotherapy (PET-2) for advanced-stage Hodgkin's lymphoma (AS-HL) is the standard of care in several countries. However,...
6.
van Heek L, Weindler J, Gorniak C, Kaul H, Muller H, Mettler J, et al.
Eur J Haematol
. 2023 Aug;
111(6):881-887.
PMID: 37644732
Objectives: The prognostic relevance of metabolic tumor volume (MTV) having recently been demonstrated in patients with early-stage favorable and advanced-stage Hodgkin lymphoma. The current study aimed to assess the potential...
7.
Heger J, Ferdinandus J, Mattlener J, Borchmann S
Semin Hematol
. 2023 Jul;
60(3):157-163.
PMID: 37422345
Hodgkin lymphoma is a B-cell lymphoma often affecting young adults. Outcomes following intensive chemo- and radiotherapy are generally favourable but leave patients at high risk for early and late toxicities...
8.
Mei R, Kessler L, Pabst K, Weber M, Schmidkonz C, Rischpler C, et al.
J Nucl Med
. 2023 May;
64(7):1043-1048.
PMID: 37230530
Ga-fibroblast activation protein inhibitors (FAPIs) are promising radiotracers for cancer imaging, with emerging data in the recent years. Nonetheless, the interobserver agreement on Ga-FAPI PET/CT study interpretations in cancer patients...
9.
Ferdinandus J, Maric I, Darr C, Kesch C, Bartel T, Fendler W, et al.
JAMA Netw Open
. 2022 Nov;
5(11):e2242289.
PMID: 36383385
No abstract available.
10.
Seifert R, Kersting D, Rischpler C, Sandach P, Ferdinandus J, Fendler W, et al.
Leukemia
. 2022 Oct;
36(12):2845-2852.
PMID: 36241697
The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that...